Immunotherapy advancesPub Date : 2026-10-30eCollection Date: 2026-01-01DOI: 10.1093/immadv/ltag025
{"title":"Correction to: Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system.","authors":"","doi":"10.1093/immadv/ltag025","DOIUrl":"https://doi.org/10.1093/immadv/ltag025","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1093/immadv/ltaf022.].</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"6 1","pages":"ltag025"},"PeriodicalIF":4.4,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13720503/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149328087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Immunotherapy advancesPub Date : 2026-10-16eCollection Date: 2026-01-01DOI: 10.1093/immadv/ltag024
Doreen Lau
{"title":"Seeing the big picture: imaging in immunotherapy.","authors":"Doreen Lau","doi":"10.1093/immadv/ltag024","DOIUrl":"https://doi.org/10.1093/immadv/ltag024","url":null,"abstract":"","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"6 1","pages":"ltag024"},"PeriodicalIF":4.4,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13711674/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149290400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Immunotherapy advancesPub Date : 2026-10-13eCollection Date: 2026-01-01DOI: 10.1093/immadv/ltag022
Zhaoyang Li, Alex Ballesteros-Perez
{"title":"Comparison of hyaluronidase-facilitated subcutaneous immunoglobulin 10% pharmacokinetics in pediatric and adult patients with primary immunodeficiency: an analysis of three phase 3 clinical trials.","authors":"Zhaoyang Li, Alex Ballesteros-Perez","doi":"10.1093/immadv/ltag022","DOIUrl":"https://doi.org/10.1093/immadv/ltag022","url":null,"abstract":"<p><strong>Introduction: </strong>Facilitated subcutaneous immunoglobulin (fSCIG) 10% is approved for the treatment of primary immunodeficiency (PID) in both pediatric and adult patients. However, it remains unclear whether there is a clinically meaningful difference in the pharmacokinetics (PK) of immunoglobulin G (IgG) between these two populations.</p><p><strong>Methods: </strong>Serum total IgG concentrations in pediatric and adult patients (aged 3-80 years) with PID from three phase 3 clinical trials of fSCIG 10% were analyzed (NCT00814320, NCT01175213, NCT03277313). Serum total IgG trough concentrations (<i>C</i> <sub>trough</sub>) were compared against the conservative threshold for treatment effectiveness of 7 g/l, and between adult and pediatric patients (aged 2 to <17 years) and pediatric subgroups (2 to <12 years and 12 to <17 years). PK parameters, including steady-state maximum concentration (<i>C</i> <sub>max</sub>), area under the curve during the dosing interval, normalized by week (AUC/week), and apparent clearance normalized for body weight (CL/F/BW), were also compared across age groups.</p><p><strong>Results: </strong>All age groups effectively achieved mean IgG <i>C</i> <sub>trough</sub> above 7 g/l following fSCIG 10% administration. Total IgG exposures (mean <i>C</i> <sub>trough</sub>, <i>C</i> <sub>max</sub>, and AUC/week) marginally increased with age (all <i>P</i> < 0.05), while there was considerable variability within age groups. However, after total IgG baseline correction, there were no differences in any exposure parameters by age. CL/F/BW remained consistent across studies and age groups.</p><p><strong>Conclusion: </strong>fSCIG 10% effectively maintains <i>C</i> <sub>trough</sub> in IgG treatment-experienced patients with PID. The small age-related differences observed in serum total IgG PK are unlikely to be clinically significant and dose adjustments by age alone are not warranted.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"6 1","pages":"ltag022"},"PeriodicalIF":4.4,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13718816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149302626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Immunotherapy advancesPub Date : 2026-10-10eCollection Date: 2026-01-01DOI: 10.1093/immadv/ltag023
João L Pereira, Nuno R Dos Santos
{"title":"Targeting the PSGL-1 glycoprotein in cancer: cellular mechanisms and emerging immunotherapeutic strategies.","authors":"João L Pereira, Nuno R Dos Santos","doi":"10.1093/immadv/ltag023","DOIUrl":"https://doi.org/10.1093/immadv/ltag023","url":null,"abstract":"<p><p>Immune checkpoint immunotherapy has transformed contemporary oncology, establishing a new paradigm across diverse malignancies. P-selectin glycoprotein ligand-1 (PSGL-1; CD162) emerged as a new immunotherapeutic target. Initially characterized as a glycosylated selectin ligand controlling leukocyte rolling, adhesion, and trafficking, PSGL-1 is now recognized as a multifunctional immunoregulatory receptor with therapeutic relevance in cancer. Its mucin-like structure, specific glycosylation, tyrosine sulfation, and cellular context enable functional interactions with several ligands, including selectins and V-domain immunoglobulin suppressor of T cell activation (VISTA). PSGL-1 is known to shape immune homeostasis, T-cell activation, effector and memory T-cell differentiation, myeloid-cell function, and tumor immune evasion. In chronic infection and cancer models, PSGL-1 restrains antigen-driven T-cell responses and contributes to dysfunctional or exhausted T-cell states, supporting its classification as a checkpoint-like regulator of immunity. Importantly, genetic deletion or antibody-mediated blockade of PSGL-1 enhances anti-tumor immunity in preclinical cancer models by increasing tumor-infiltrating T-cell activation and promoting immunostimulatory myeloid phenotypes. These changes in tumor-infiltrating immune cells are associated with reduction of tumor growth, synergism with PD-1/PD-L1 blockade, and improvement of chimeric antigen receptor (CAR) T-cell therapy. In blood cancers, where PSGL-1 is often expressed in malignant cells, PSGL-1 contributes to malignant cell homing, tissue dissemination, chemoresistance, and antibody-induced tumor-cell apoptosis. Overall, PSGL-1 represents a promising candidate for next-generation cancer immunotherapy, with potential to stimulate anti-tumor immunity, remodel the tumor microenvironment, and target malignant hematopoietic cell properties.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"6 1","pages":"ltag023"},"PeriodicalIF":4.4,"publicationDate":"2026-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685773/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149247811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"CAR-T cell-induced cytokine release syndrome is rapidly alleviated by Tripterygium glycosides: a case series and laboratory examination study.","authors":"Zuqiong Xu, Fang Tian, Biqing Chen, Xiangtu Kong, Xingbin Dai, Jiang Cao, Pengjun Jiang, Xuejun Zhu","doi":"10.1093/immadv/ltag021","DOIUrl":"10.1093/immadv/ltag021","url":null,"abstract":"<p><strong>Background: </strong>Cytokine release syndrome (CRS) is a life-threatening complication of chimeric antigen receptor T cell (CAR-T) therapy. Macrophages/monocytes are mediators of CRS. Tripterygium glycosides is an immunomodulator, which could inhibit macrophages/monocytes in animal models.</p><p><strong>Methods: </strong>Two patients with relapsed and refractory hematological malignancies developed CRS after receiving CAR-T therapy. They received short-term Tripterygium glycosides orally.</p><p><strong>Results: </strong>Both patients showed rapid mitigation of fever with evidently decrease in elevated inflammatory cytokines within 72 hours. The patients' monocytes diminished remarkably, while CAR-T cells were negligibly affected. Treatment of 30 ng/ml triptolide in <i>ex vivo</i> cultured patients' blood for 24 hours selectively deplete over half of monocytes. Single-cell RNA sequencing suggested selective depletion of CD14 <sup>+</sup> CD16<sup>+</sup> monocytes with decreased pro-inflammatory cytokines.</p><p><strong>Conclusion: </strong>The low-cost and orally available Tripterygium glycosides could be a promising alternative for CAR-T induced CRS, as well as other diseases complicated with CRS, e.g. coronavirus disease 2019.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"6 1","pages":"ltag021"},"PeriodicalIF":4.4,"publicationDate":"2026-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13669633/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149217404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Immunotherapy advancesPub Date : 2026-09-16eCollection Date: 2026-01-01DOI: 10.1093/immadv/ltag014
Takahiro Tomoda, Ai Kawana-Tachikawa, Shigeomi Shimizu, Satoshi Takahashi, Hirokazu Kanegane, Takahiro Kamiya, Kumi Inoue, Masatoshi Takagi, Tomohiro Morio
{"title":"L-Arginine supplementation improves the survival of virus-specific CD8<sup>+</sup> T cells during <i>in vitro</i> expansion.","authors":"Takahiro Tomoda, Ai Kawana-Tachikawa, Shigeomi Shimizu, Satoshi Takahashi, Hirokazu Kanegane, Takahiro Kamiya, Kumi Inoue, Masatoshi Takagi, Tomohiro Morio","doi":"10.1093/immadv/ltag014","DOIUrl":"https://doi.org/10.1093/immadv/ltag014","url":null,"abstract":"<p><strong>Introduction: </strong>Virus-specific T cell therapy is a promising treatment for life-threatening viral infections following allogeneic hematopoietic stem cell transplantation. However, its efficacy is limited by apoptotic cell loss during <i>in vitro</i> expansion and the cryopreservation process.</p><p><strong>Materials and methods: </strong>Human virus-specific T cells were expanded <i>in vitro</i> with interleukin-7 and interleukin-15 in RPMI 1640-based medium with or without L-arginine supplementation, and their survival, phenotype, mitochondrial function, and cytokine signaling were evaluated.</p><p><strong>Results: </strong>Supplementation of the culture medium with L-arginine enhanced the survival of human virus-specific T cells during <i>in vitro</i> expansion. Supplementation of the RPMI 1640-based culture medium with L-arginine reduced apoptosis and was accompanied by increased expression of the anti-apoptotic protein MCL-1 in virus-specific CD8<sup>+</sup> T cells. In parallel, modest differences in exhaustion- and differentiation-associated markers were observed. Consistent with these survival-associated changes, preservation of mitochondrial membrane potential was concurrently observed in non-apoptotic CD8<sup>+</sup> T cells. Among several culture-associated factors that may contribute to mitochondrial preservation, L-arginine availability was associated, at least in part, with common gamma-chain cytokine-induced phosphorylation of mammalian target of rapamycin signalling and signal transducer and activator of transcription 5 downstream of interleukin-7 and interleukin-15 during <i>in vitro</i> culture.</p><p><strong>Conclusion: </strong>Together, these findings support L-arginine supplementation as a simple and clinically applicable strategy to enhance the durability of virus-specific T cell products during <i>in vitro</i> expansion, as well as cryopreservation and thawing.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"6 1","pages":"ltag014"},"PeriodicalIF":4.4,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13580084/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148992744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Immunotherapy advancesPub Date : 2026-08-14eCollection Date: 2026-01-01DOI: 10.1093/immadv/ltag020
Lan Huynh, Abdullah Aljohani, Amal Alsubaiti, Tressan Grant, Alexandra Chapman, Gwilym Phillips, Jonathan Chamberlain, Alice Hayward-Wills, Ute Jungwirth, Mariolina Salio, Christopher J Holland, Christoph Wülfing
{"title":"ImmTACs overcome cytotoxic T cell suppression.","authors":"Lan Huynh, Abdullah Aljohani, Amal Alsubaiti, Tressan Grant, Alexandra Chapman, Gwilym Phillips, Jonathan Chamberlain, Alice Hayward-Wills, Ute Jungwirth, Mariolina Salio, Christopher J Holland, Christoph Wülfing","doi":"10.1093/immadv/ltag020","DOIUrl":"10.1093/immadv/ltag020","url":null,"abstract":"<p><strong>Introduction: </strong>Synthetic T cell receptor (TCR) engagers are cancer therapeutics that activate T cells through recognition of antigens on the tumor cell surface. Immune-mobilizing monoclonal TCRs against cancer (ImmTAC) are composed of the extracellular domains of the alpha and beta chains of an affinity-enhanced TCR recognizing a tumor-associated antigenic peptide-major histocompatibility complex (MHC) complex linked to an scFv fragment of an antibody against CD3ε. A first-in-class ImmTAC, Tebentafusp, is approved for the treatment of metastatic uveal melanoma. Here we asked how ImmTACs activate human primary cytotoxic T lymphocytes (CTL) in response to antigen-presenting tumor target cells.</p><p><strong>Materials and methods: </strong>We used a recently established experimental strategy to generate active and matched suppressed CTL <i>in vitro</i>.</p><p><strong>Results: </strong>ImmTACs could elicit tumor cell cytolysis in response to endogenous antigen presentation by both active and suppressed CTL, but much less so for IFNγ secretion, in a manner dependent on the engager affinity for CD3ε. ImmTACs did so by enhancing the efficient execution of subcellular CTL polarization steps required for effective cytolysis and could trigger calcium signaling.</p><p><strong>Conclusion: </strong>These data establish that ImmTACs are powerful inducers of CTL cytotoxicity and do so with a comparable efficacy and mechanism as direct engagement of a TCR by peptide-MHC. ImmTACs retain this capability under suppressive conditions comparable to those in the tumor microenvironment.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"6 1","pages":"ltag020"},"PeriodicalIF":4.4,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13593617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149026956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Immunotherapy advancesPub Date : 2026-08-11eCollection Date: 2026-01-01DOI: 10.1093/immadv/ltag018
Vered Schichter Konfino, Oded Shamriz
{"title":"IVIG-associated anterior uveitis resolving after switch to subcutaneous immunoglobulin.","authors":"Vered Schichter Konfino, Oded Shamriz","doi":"10.1093/immadv/ltag018","DOIUrl":"10.1093/immadv/ltag018","url":null,"abstract":"<p><strong>Introduction: </strong>Intravenous immunoglobulin (IVIG) therapy can occasionally induce unexpected inflammatory complications.</p><p><strong>Materials and methods: </strong>A case report and literature review.</p><p><strong>Results: </strong>We report a patient with hypogammaglobulinemia and systemic autoimmunity who developed reproducible unilateral anterior uveitis following IVIG administration across multiple formulations. Discontinuation of IVIG resolved the ocular inflammation but caused underlying disease exacerbation. Transition to facilitated subcutaneous immunoglobulin (SCIG) achieved stable serum IgG levels and maintained complete ocular and systemic remission over a four-year follow-up period.</p><p><strong>Conclusion: </strong>This case demonstrates peak-driven immune activation as a plausible mechanism for IVIG-induced uveitis and highlights SCIG as a safe, effective therapeutic alternative that bypasses rapid peak IgG dynamics while preserving immune protection.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"6 1","pages":"ltag018"},"PeriodicalIF":4.4,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13511136/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148835381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Safety and efficacy of PRaG therapy in elderly cancer patients.","authors":"Xiangrong Zhao, MengMeng Yang, Junjun Zhang, Yuehong Kong, Meiling Xu, Rongzheng Chen, Qian Yin, Pengfei Xing, Liyuan Zhang","doi":"10.1093/immadv/ltag019","DOIUrl":"10.1093/immadv/ltag019","url":null,"abstract":"<p><strong>Introduction: </strong>PD-1/PD-L1 inhibitors lack evidence-based support in patients aged ≥75 years due to their frequent exclusion from clinical trials. This study aimed to evaluate the safety and efficacy of PRaG therapy-combining PD-1/PD-L1 inhibitors with radiotherapy-specifically in this elderly demographic.</p><p><strong>Materials and methods: </strong>Data were collected from patients aged ≥75 years who received PRaG therapy at our center between 1 January 2019, and 31 December 2024. Eligible patients were required to have at least one post-baseline efficacy evaluation. Tumor response was evaluated according to RECIST v1.1, and adverse events were graded using CTCAE v5.0.</p><p><strong>Results: </strong>A total of 36 elderly patients aged ≥75 years were included, with a median age of 77 years (range: 75-93). The objective response rate (ORR) was 23.5%, and the disease control rate (DCR) was 70.6%. After a median follow-up of 46.3 months, the median progression-free survival (mPFS) was 7.0 months (95% CI: 2.4-11.6 months) and the median overall survival (mOS) was 11.1 months (95% CI: 5.3-16.9 months). The Geriatric Nutritional Risk Index (GNRI) was associated with the efficacy of PRaG therapy, as well as PFS and OS. Any-grade treatment-related adverse events (TRAEs) occurred in 34 patients (94.4%), with 3 patients (8.3%) experiencing ≥Grade 3 TRAEs. No Grade 5 TRAEs were observed.</p><p><strong>Conclusion: </strong>The PRaG regimen appears feasible and tolerable in selected elderly patients with advanced cancer. Given the retrospective nature of this small cohort, an ongoing prospective trial (NCT06112041) will further validate these findings. Combining PRaG with robust nutritional support represents a rational hypothesis for future investigation.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"6 1","pages":"ltag019"},"PeriodicalIF":4.4,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148889417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Immunotherapy advancesPub Date : 2026-07-22eCollection Date: 2026-01-01DOI: 10.1093/immadv/ltag016
Rosela H Webster, Alexandra R Dvorscek, Zhoujie Ding, David M Tarlinton, Marcus J Robinson
{"title":"Radiation resistance is a property of long-lived plasma cells but not their precursors.","authors":"Rosela H Webster, Alexandra R Dvorscek, Zhoujie Ding, David M Tarlinton, Marcus J Robinson","doi":"10.1093/immadv/ltag016","DOIUrl":"10.1093/immadv/ltag016","url":null,"abstract":"<p><strong>Introduction: </strong>Irradiation and reconstitution has often been used to analyze plasma cell turnover. Here, we characterized the kinetics of plasma cell reconstitution following irradiation, focusing on representation of recipient and donor plasma cells.</p><p><strong>Materials and methods: </strong>In a first setup, bone marrow chimeras were generated using congenic Ly5 allotype marked bone marrow transfer after lethal X-ray irradiation. Representation of donor and recipient B cells and plasma cells were tracked in the weeks thereafter. In a second setup, we repeated the reconstitution using plasma cell timestamp mice as recipients and BLIMP1<sup>gfp</sup> as donor bone marrow, allowing tracing of both recipient- and donor-source plasma cells with fluorescent reporters.</p><p><strong>Results: </strong>In recipient spleen and bone marrow in the first setup, B cell and plasma cell numbers returned to homeostasis within 4 weeks of reconstitution. We determined that while B cells were essentially donor-derived by 4 weeks and plasma cells reached maximum donor representation at 4 weeks, they retained a significant fraction of recipient origin plasma cells to at least 8 weeks, the experiment endpoint. This clearly resolved plasma cell origin and revealed recipient plasma cells comprised both persistent and newly formed, the latter being the majority. When irradiated, timestamped mice were reconstituted with B-cell-insufficient µMT bone marrow, leaving irradiated recipient B cells as the sole source of new plasma cells, the recipients generated significantly more nascent plasma cells from endogenous B cells than occurred in the BLIMP1<sup>gfp</sup> recipients.</p><p><strong>Conclusion: </strong>These data suggest that irradiated B cells are at a disadvantage to donor-derived B cells but can give rise to plasma cells when competition is alleviated, here by donor B-cell lymphopenia. Bone marrow reconstitution after irradiation thus reveals a population of radiation resistant long-lived plasma cells and B cell or early-stage plasma cell competition for production and retention.</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"6 1","pages":"ltag016"},"PeriodicalIF":4.4,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13591278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149018990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}